Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024)

Fulcrum Therapeutics (FULC) reported Restructuring Costs of $2.1 million for Q3 2024, up 5528.95% quarter-over-quarter from -$38000.0 in Q4 2022.

Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024) Analysis & Trends

Fulcrum Therapeutics (FULC) has 2 years of Restructuring Costs data on file, last reported at $2.1 million in Q3 2024.

Restructuring Costs for Q3 2024 came in at $2.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.1 million (changed 0.0% YoY), and the FY2024 annual result was $2.1 million, changed N/A from the prior year.
Restructuring Costs climbed to $2.1 million in Q3 2024 per FULC's latest filing, from -$38000.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $2.1 million in Q3 2024 and troughed at -$38000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Fulcrum Therapeutics	267.90 Mn	267.90 Mn	-

Download Data